Reyes A J, Leary W P
Institute of Cardiovascular Theory, Montevideo, Uruguay.
Cardiovasc Drugs Ther. 1993 Jan;7 Suppl 1:29-44. doi: 10.1007/BF00877956.
Administration of an initial oral dose of hydrochlorothiazide 25 mg to healthy subjects is followed by increased 24-hour urinary outputs of sodium, chloride, and potassium. On the fourth day of once-daily dosing with hydrochlorothiazide 25 mg, 24-hour natriuresis and chloriuresis are no longer augmented, but the elevation in 24-hour kaliuresis that follows the first dose remains unchanged. Twenty-four-hour urinary calcium output is consistently reduced during repeated once-daily administration of hydrochlorothiazide 25 mg. The first oral dose of the loop diuretic torasemide augments the average natriuresis and kaliuresis in the 6 hours immediately after dosing in healthy subjects, in a dose-dependent fashion, within the 2.5 to 10-mg range. These increased urinary outputs are followed by rebounds below postplacebo values between 6 and 24 hours after dosing. As a result of this biphasic response, torasemide 2.5 mg qualifies as a nondiuretic formulation (it does not elevate 24-hour natriuresis), whereas torasemide 5 and 10 mg qualify as diuretic formulations. After the seventh dose of torasemide 5 or 10 mg during a regimen of once-daily therapy, 24-hour urinary sodium and chloride outputs no longer differ from their postplacebo counterparts. Twenty-four-hour kaliuresis tends to increase in a dose-dependent fashion after the first dose of torasemide (torasemide 2.5 and 5 mg do not augment it significantly), but this tendency is no longer present after the seventh once-daily dose, when torasemide (2.5, 5, or 10 mg) does not elevate the mean 24-hour kaliuresis. Twenty-four-hour calciuresis tends to increase in a dose-dependent manner (torasemide 2.5 mg does not elevate it significantly) after the first dose of torasemide; this calciuretic effect does not change in intensity after 7 days of once-daily treatment. The time course of natriuresis over the 24 hours following the administration of any given formulation of a loop or of an early distal tubular diuretic to healthy subjects is alike after the first and after the nth once-daily dose; therefore, it constitutes a definite characteristic of any given oral formulation. In the case of torasemide, lower doses have more protracted effects on natriuresis, to the extent that the time course of natriuresis over the 24 hours after administration of torasemide 2.5 mg to healthy subjects resembles the time course after administration of hydrochlorothiazide 25 mg, rather than the time course after administration of the overtly diuretic formulation torasemide 10 mg.
给健康受试者口服初始剂量的25mg氢氯噻嗪后,24小时尿钠、氯和钾的排出量增加。在每日一次服用25mg氢氯噻嗪的第四天,24小时尿钠排泄和氯排泄不再增加,但首次给药后24小时尿钾排泄的升高保持不变。在每日重复一次服用25mg氢氯噻嗪期间,24小时尿钙排出量持续减少。袢利尿剂托拉塞米的首次口服剂量在2.5至10mg范围内,以剂量依赖的方式增加健康受试者给药后立即出现的6小时内的平均尿钠排泄和尿钾排泄。这些尿量增加之后,在给药后6至24小时内会出现低于安慰剂后值的反弹。由于这种双相反应,2.5mg托拉塞米可被视为非利尿制剂(它不会提高24小时尿钠排泄),而5mg和10mg托拉塞米可被视为利尿制剂。在每日一次治疗方案中,服用第七剂5mg或10mg托拉塞米后,24小时尿钠和氯排出量与安慰剂后的值不再有差异。首次服用托拉塞米后,24小时尿钾排泄倾向于以剂量依赖的方式增加(2.5mg和5mg托拉塞米不会显著增加),但在每日一次服用第七剂后,这种倾向不再存在,此时托拉塞米(2.5mg、5mg或10mg)不会提高平均24小时尿钾排泄。首次服用托拉塞米后,24小时尿钙排泄倾向于以剂量依赖的方式增加(2.5mg托拉塞米不会显著提高);在每日一次治疗7天后,这种促钙尿作用的强度没有变化。给健康受试者服用任何一种袢利尿剂或早期远曲小管利尿剂的给定制剂后在24小时内尿钠排泄的时间过程,在首次和第n次每日一次给药后是相似的;因此,它构成了任何给定口服制剂的一个明确特征。就托拉塞米而言,较低剂量对尿钠排泄的作用持续时间更长,以至于给健康受试者服用2.5mg托拉塞米后24小时内尿钠排泄的时间过程类似于服用25mg氢氯噻嗪后的时间过程,而不是类似于明显利尿制剂10mg托拉塞米给药后的时间过程。